Global observational study on ranibizumab in real-life clinical practice enrolling worldwide

The LUMINOUS study, the first global, large-scale observational study on ranibizumab in routine clinical practice, is successfully enrolling subjects worldwide.According to Paul Mitchell, MD, steering committee member, the study will provide evidence of the long-term safety, effectiveness, treatment patterns and quality of life of patients treated with Lucentis (ranibizumab, Novartis/Genentech) in the real-life scenario of clinical practice worldwide.Five hundred sites in 36 countries are in the process of recruiting 40,000 patients who will be followed for 6 years. Currently, 12,500 patients have been included.

Full Story →